News & Updates
Filter by Specialty:
Response to therapy higher in clinical trial than real-world RCC patients
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023
Menopausal hormone therapy use carries increased T2DM risk
The use of menopausal hormone therapy (MHT), including the most prescribed agent tibolone, appears to contribute to an increase in the risk of type 2 diabetes mellitus (T2DM), as shown in a retrospective study.
Menopausal hormone therapy use carries increased T2DM risk
21 Mar 2023
PCSK9 inhibition tied to decreased psoriasis risk
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.
PCSK9 inhibition tied to decreased psoriasis risk
20 Mar 2023
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
Use of telbivudine (LdT) during the second trimester of pregnancy helps prevent mother-to-child transmission of hepatitis B virus, reveals a study. In addition, treatment with LdT during pregnancy is safe in the long term for both mothers and infants.
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
20 Mar 2023
Add-on amantadine of no help in hospitalized COVID-19 patients
The addition of amantadine to standard care falls short of improving the likelihood of recovery of patients hospitalized with COVID-19, according to a study.